Press releases

BioArctic and Eisai present new data regarding BAN2401 at the Alzheimer’s Association International Conference 2019

July 18, 2019 - Other press release

Stockholm, Sweden, July 18, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that new data related to BAN2401 were presented on July 17. The ...

BioArctic’s co-founder received AAIC Lifetime Achievement Award

July 15, 2019 - Other press release

Professor Lars Lannfelt received prestigious international award for outstanding research in Alzheimer’s disease

Interim Report January – June 2019

July 11, 2019 - Regulatory press release

BioArctic: Significant progress in the projects and additional milestone payment

BioArctic and Eisai to present BAN2401 at the Alzheimer’s Association International Conference 2019

July 11, 2019 - Other press release

  Stockholm, Sweden, July 11, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that presentations related to BAN2401 will be given at ...

Invitation to presentation of BioArctic’s Interim Report for the second quarter of 2019 on July 11 at 9.30 a.m. CET

July 2, 2019 - Other press release

Stockholm, Sweden, July 2, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – June 2019 ...

BioArctic strengthens its blood-brain barrier technology platform with world leading scientist recruitment

May 23, 2019 - Other press release

Stockholm, Sweden, May 23, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has recruited the internationally renowned scientist Dr. ...

BioArctic receives MEUR 15 milestone payment from Eisai for start of BAN2401 confirmatory Phase 3 study in early Alzheimer’s Disease

May 20, 2019 - Regulatory press release

Stockholm, Sweden, May 20, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company will receive a milestone payment of MEUR ...

BioArctic: Alzheimer’s Clinical Trials Consortium and Eisai announce BAN2401 to be evaluated in clinical study for prevention of Alzheimer’s disease

May 10, 2019 - Other press release

Stockholm, Sweden, May 10, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) informed today that the Alzheimer’s Clinical Trials Consortium (ACTC) and BioArctic’s partner ...

BioArctic’s Board of Directors and management increase their shareholdings

May 9, 2019 - Other press release

Stockholm, Sweden, May 9, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that nine members of the company's Board and management today have called ...

BioArctic – report from the Annual General Meeting 2019

May 9, 2019 - Regulatory press release

Stockholm, Sweden, May 9, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today held its Annual General Meeting 2019. The following resolutions were adopted:

Interim Report January – March 2019

May 9, 2019 - Regulatory press release

BioArctic’s partner Eisai initiated Phase 3-study with BAN2401 in Alzheimer’s disease. Phase 1-study with ABBV-0805 in the Parkinson program started 

Invitation to presentation of BioArctic’s Interim Report for the first quarter of 2019 on May 9, at 9.30 a.m. CET

April 29, 2019 - Other press release

Stockholm, Sweden, April 29, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – March 2019 ...

BioArctic publishes the Annual Report for 2018

April 16, 2019 - Regulatory press release

Stockholm, Sweden, April 16, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the Annual Report for the 2018 fiscal year has been ...

Notice of Annual General Meeting in BioArctic AB (publ)

April 10, 2019 - Regulatory press release

The shareholders in BioArctic AB (publ), corporate identity number 556601-2679 (”the Company”) are hereby summoned to the Annual General Meeting to be held on May 9, ...

BioArctic receives grant from Vinnova for a collaborative research project to increase brain uptake of antibodies

April 3, 2019 - Other press release

Stockholm, Sweden, April 3, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received a non-diluting grant of MSEK 5 ...

BioArctic’s partner Eisai to give poster presentations on BAN2401 in early Alzheimer’s disease at the AD/PD conference in Lisbon

March 25, 2019 - Other press release

Stockholm, Sweden, March 25, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that its partner Eisai will give poster presentations related to BAN2401 in ...

BioArctic’s partner Eisai initiates the confirmatory Phase 3 study of BAN2401 in early Alzheimer’s Disease

March 22, 2019 - Regulatory press release

Stockholm, Sweden, March 22, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that its partner Eisai has initiated the global Phase 3 confirmatory ...

BioArctic – Statement regarding today’s trading halt

March 21, 2019 - Regulatory press release

Stockholm, Sweden, March 21, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) comments on the decision today by Nasdaq Stockholm to halt trading in BioArctic ...

BioArctic announces start of Phase 1 study of ABBV-0805 for Parkinson’s disease

March 13, 2019 - Regulatory press release

Stockholm, Sweden, March 13, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first clinical study with ABBV-0805 has started in the ...

BioArctic: Eisai announces timelines for the single confirmatory Phase 3 study with BAN2401 in early Alzheimer’s disease

March 7, 2019 - Regulatory press release

Stockholm, Sweden, March 7, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) informs that Eisai today announced the timelines for the single confirmatory Phase 3 ...

Full Year Report January – December 2018

February 14, 2019 - Regulatory press release

BioArctic’s partner Eisai will initiate BAN2401 confirmatory Phase 3-study in early Alzheimer’s disease. AbbVie in-licensed the Parkinson portfolio

BioArctic’s product candidate SC0806 for treatment of patients with complete spinal cord injury is now in Phase 2

February 13, 2019 - Regulatory press release

Stockholm, Sweden, February 13, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient in the second panel of the Phase ...

BioArctic: U.S. Food and Drug Administration Approves Investigational New Drug Application for ABBV-0805

February 11, 2019 - Regulatory press release

ABBV-0805 is being evaluated as a potential disease modifying treatment for Parkinson’s Disease Stockholm, Sweden, February 11, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA ...

Invitation to presentation of BioArctic’s Full Year Report 2018 on February 14, 2019

February 7, 2019 - Other press release

Stockholm, Sweden, February 7, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Full Year Report for the period January – December ...

BioArctic announces that Eisai will initiate Phase 3 confirmatory study with BAN2401 in early Alzheimer’s Disease

February 4, 2019 - Regulatory press release

Stockholm, Sweden, February 4, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that Eisai stated at their Q3 FY2018 Financial Results Meeting on ...